Moonlake Immunotherapeutics (MLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -74,849 | -38,734 | -13,975 | -44,079 | -36,192 |
| Depreciation Amortization | 1,021 | 670 | 328 | 370 | 10 |
| Accounts receivable | -1,350 | -620 | -439 | -840 | -504 |
| Accounts payable and accrued liabilities | 8,873 | 3,305 | 1,645 | 1,583 | 3,150 |
| Other Working Capital | 118 | -8,165 | -2,845 | -6,218 | 202 |
| Other Operating Activity | -1,927 | 706 | 338 | 6,406 | 2,900 |
| Operating Cash Flow | $-68,114 | $-42,838 | $-14,948 | $-42,778 | $-30,434 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -57,921 | -116,335 | -28,592 | -24,900 | -142,051 |
| PPE Investments | -344 | -212 | -212 | -284 | N/A |
| Investing Cash Flow | $-58,265 | $-116,547 | $-28,804 | $-25,184 | $-142,051 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 52,540 | 52,540 | 52,540 | 482,454 | 451,285 |
| Other Financing Activity | -1,379 | -1,562 | -1,562 | -2,753 | 0 |
| Financing Cash Flow | $51,161 | $50,978 | $50,978 | $479,701 | $451,285 |
| Exchange Rate Effect | -296 | 29 | 46 | -76 | -140 |
| Beginning Cash Position | 451,169 | 451,169 | 451,169 | 39,506 | 39,506 |
| End Cash Position | 375,655 | 342,791 | 458,441 | 451,169 | 318,166 |
| Net Cash Flow | $-75,514 | $-108,378 | $7,272 | $411,663 | $278,660 |
| Free Cash Flow | |||||
| Operating Cash Flow | -68,114 | -42,838 | -14,948 | -42,778 | -30,434 |
| Capital Expenditure | -344 | -212 | -212 | -284 | 0 |
| Free Cash Flow | -68,458 | -43,050 | -15,160 | -43,062 | -30,434 |